Adalimumab in the treatment of immune-mediated diseases. - Wikidata - awgldk - TriplyDB

Adalimumab in the treatment of immune-mediated diseases.

Adalimumab in the treatment of immune-mediated diseases.

http://www.wikidata.org/entity/Q38207760

about

Anti-TNF agents for paediatric psoriasis Risk factors for osteoporosis in inflammatory bowel disease patients Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials Stereomicroscopic 3D-pattern profiling of murine and human intestinal inflammation reveals unique structural phenotypes Exogenous IFN-beta regulates the RANKL-c-Fos-IFN-beta signaling pathway in the collagen antibody-induced arthritis model.TNF-α Modulation of Intestinal Tight Junction Permeability Is Mediated by NIK/IKK-α Axis Activation of the Canonical NF-κB Pathway.An introduction to biomaterial-based strategies for curbing autoimmunity.Peptide- and Amine-Modified Glucan Particles for the Delivery of Therapeutic siRNA.Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.Polymorphonuclear neutrophils in periodontitis and their possible modulation as a therapeutic approach.IgG4-related disease presenting as panuveitis without scleral involvement.Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells.Calpain-2 Inhibitor Therapy Reduces Murine Colitis and Colitis-associated Cancer.Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren's syndrome treated with Infliximab: a pilot study.Economic evaluation of spondyloarthritis: economic impact of diagnostic delay in Italy.Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors.Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study.Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease.

P2860

Q24187673-FAB4F114-4276-41C2-AB0B-0C0532DB3B88 Q26776142-7E2A6C56-83B5-41F5-B102-335EC7D17874 Q28070298-F3B0CEBD-2985-4B58-AC31-0F199773CBB2 Q30658529-F7DAAEAE-F1E8-4D06-9A9A-A6A97842E4D1 Q34751981-DF825E87-9537-42A9-854F-25BCE49254A7 Q36885702-8C4D37DB-6227-49B2-BEBF-8C188C475ACA Q37107172-36350B06-79B1-49C3-AAF6-0CE20169B4C9 Q37498037-022CDF39-95FB-48C7-B56D-7FBFF2381249 Q38645738-5AE49969-57BD-4F6D-B25A-40CAC161B484 Q38798358-AB470431-6592-4354-BE6F-4A4A874344E4 Q39154005-255696E1-C79D-4183-9C40-E60B8F78254E Q40716797-F3626895-D2DC-4479-9135-E59F4EA1C835 Q42588907-D845A309-6BE8-4BD9-A2AA-38A392E1361A Q42741713-1F08D0B0-EA7E-4705-B072-D839E1F3932F Q49387423-1796E677-16D9-44D9-ADD5-E68DD32F6D1D Q50224633-6B56BFF0-473F-4BB0-8912-A1B4F02E20CF Q51692022-56719666-E0E8-4CFE-B481-FA622FB69E0F Q54961768-99EFD275-464D-4EE8-84DE-FC08B8642CF3 Q55007606-E6085D89-12A8-43AE-895C-160F46A9C245 Q55216456-F5D96738-5CAE-4298-A436-1D1EAD2CB2C1

P2860

Adalimumab in the treatment of immune-mediated diseases.

http://www.wikidata.org/entity/Q38207760

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Adalimumab in the treatment of immune-mediated diseases.

@en

type

label

Adalimumab in the treatment of immune-mediated diseases.

@en

prefLabel

Adalimumab in the treatment of immune-mediated diseases.

@en

P1433

Q38207760-379EC457-90D4-4AD5-BBE2-C7A109A77FF0

P1476

Q38207760-5AE6956E-1938-4ABE-B7E0-F404C461E86C

P2093

Q38207760-18DAB97D-F0EE-4D90-9B05-4C617C5E6750

Q38207760-20ACC3F7-2A6B-40FC-A07C-A55F2268861F

Q38207760-39683055-5A85-4171-84E4-937449CFD2AE

Q38207760-583F5C46-20B5-4F01-99FD-3C5465473BAE

Q38207760-7F5E464B-042C-400B-B276-EEC0A6537DCC

Q38207760-A9BA5583-E8CC-4C41-A89F-1FCEF5E0C6EF

Q38207760-E4A4A8A3-366F-435C-81CE-6337D33E04A1

Q38207760-ED0EC78B-2D5F-481A-81F7-941CF91F9471

P2860

Q38207760-055FB1B6-EB1E-42C1-8DAC-A576BBA21480

Q38207760-062F33EB-C562-4CEB-8394-D4B031062704

Q38207760-0AD62A4C-6E63-4D72-80F0-1632C0EB08DD

Q38207760-0E3956C1-6D07-4102-8867-41771B86A8EE

Q38207760-10BFE877-7AA2-4E13-B222-B0619A2E2489

Q38207760-17200587-133F-4B9E-ABB0-FC0F4F256E80

Q38207760-191A7BB3-6F75-419A-8A52-D8247D7FCAE7

Q38207760-19568E3D-3FB9-4E09-85E0-D0937C6D7E91

Q38207760-1ABCCEE0-B243-472A-9729-5549DF4836FC

Q38207760-1E4DBFD2-1FBD-465E-8948-2C15DB628E21

P304

Q38207760-E8B448EE-2439-4598-A2F9-C0C14418C44F

P31

Q38207760-0FE07760-0C7C-46BF-8CE5-DB8336C0FE69

P356

Q38207760-37041C54-1A3D-4573-A5DC-AC96DBD9B044

P433

Q38207760-D1732AAA-C5FB-4923-87A7-9BB60FDEA988

P478

Q38207760-705655EE-2832-4241-A235-C2F41308DBFB

P50

Q38207760-68E08999-E33C-402A-9DE2-7AEFC361567C

Q38207760-B27D9A90-965C-4DBA-82E1-2E61E95A66AA

Q38207760-B5139F69-1C26-4F02-A440-072402F34671

Q38207760-C209261A-A52C-4391-8BB8-0082F4250A0E

Q38207760-D04040EC-23CF-47C8-98B5-397D530152A4

Q38207760-F10978DA-7D94-496B-93DC-08D21A301E74

P577

Q38207760-C678E270-53A8-450B-9790-02AC0592F249

P698

Q38207760-B672DE61-C2A4-42E4-81AF-ABFC57E54537

P921

Q38207760-50D78440-2F34-4A94-9542-B481AA859135

P356

03946320140270S103

P1433

International Journal of Immunopathology and Pharmacology

P1476

Adalimumab in the treatment of immune-mediated diseases.

@en

P2093

A Armuzzi

http://www.w3.org/2001/XMLSchema#string

A Marchesoni

http://www.w3.org/2001/XMLSchema#string

F S Mennini

http://www.w3.org/2001/XMLSchema#string

G Girolomoni

http://www.w3.org/2001/XMLSchema#string

L Cimino

http://www.w3.org/2001/XMLSchema#string

P Gionchetti

http://www.w3.org/2001/XMLSchema#string

P Lionetti

http://www.w3.org/2001/XMLSchema#string

S Chimenti

http://www.w3.org/2001/XMLSchema#string

P2860

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Connections between psoriasis and Crohn's disease.

Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

P304

33-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/03946320140270S103

http://www.w3.org/2001/XMLSchema#string

P433

1 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Carlo Salvarani

Giovanni Lapadula

Andrea Marcellusi

Corrado Blandizzi

Roberto Caporali

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24774505

http://www.w3.org/2001/XMLSchema#string

P921